Extremely Rare Disease Consideration

Extremely rare disease consideration addresses pharmaceutical development for diseases affecting <1 per 100,000 population making traditional trial designs infeasible. Orphan drug designations provide regulatory incentives including exclusivity extensions. Single-arm trials or case series replace traditional comparator arms acknowledging inability to enrol adequate populations. Surrogate endpoint acceptance streamlines approval processes.

International collaboration pools limited patient populations across countries. Patient registries establish disease natural history informing trial interpretation. Regulatory flexibility permits adaptive designs maximising available data. Fast-track and breakthrough designations accelerate development timelines. Compassionate use programmes provide pre-approval access. Health economic analysis accounts for small population economics.